Screening Labs Before Starting GLP-1 Receptor Agonist in Elderly Women
Before initiating a GLP-1 receptor agonist in a 75-year-old woman with type 2 diabetes, order the following screening labs: comprehensive metabolic panel (including renal function with eGFR and electrolytes), HbA1c, lipid panel, thyroid function tests (TSH at minimum), and urinalysis with urine albumin-to-creatinine ratio.
Essential Laboratory Tests
Renal Function Assessment
- Comprehensive metabolic panel with eGFR is critical because GLP-1 RAs demonstrate significant kidney benefits, particularly in patients with eGFR 30-60 mL/min/1.73m² or albuminuria 1
- Baseline renal function guides both medication selection and monitoring for the 17% reduction in broad kidney composite outcomes seen with these agents 1
- This is especially important in elderly patients where age-related renal decline is common
Glycemic Control Baseline
- HbA1c establishes baseline glycemic control, though notably, the decision to use GLP-1 RAs in high-risk patients should be made independently of baseline HbA1c levels 1
- This helps track therapeutic response and guides dose titration
Thyroid Screening
- TSH (thyroid stimulating hormone) is essential because GLP-1 RAs may confer an increased risk for thyroid cancer 2
- This establishes a baseline for monitoring, particularly important in elderly women who have higher baseline thyroid disease prevalence
Cardiovascular and Metabolic Risk Assessment
- Lipid panel helps stratify cardiovascular risk, which is crucial since GLP-1 RAs show greatest MACE benefit in patients with established atherosclerotic CVD or high-risk indicators 1
- Liver function tests (included in CMP) screen for hepatic impairment
Kidney Disease Markers
- Urine albumin-to-creatinine ratio (UACR) identifies albuminuria, a key indicator for GLP-1 RA use, as benefits are particularly pronounced with UACR >30 mg/g and especially >300 mg/g 1
Critical Pre-Treatment Considerations
Retinal Screening
While not a "lab," ophthalmologic examination is mandatory before initiation. Sight-threatening eye complications can result from rapid glycemic reductions, which can be avoided by retinal screening and treatment before GLP-1 RA initiation 2. This is particularly important in elderly patients with long-standing diabetes.
Special Caution in Elderly Patients
The Japan Geriatrics Society added GLP-1 RAs to drugs requiring special caution in elderly patients in 2025 3. In real-world practice, 63% of elderly GLP-1 RA users had obesity and were on an average of 3.2 concomitant glucose-lowering drugs 3, highlighting the complexity of management in this population.
Clinical Pitfalls to Avoid
Polypharmacy Assessment
Review all current glucose-lowering medications, as GLP-1 RAs are frequently prescribed with other drugs requiring special caution (metformin, SGLT2 inhibitors, sulfonylureas, insulin) 3. Baseline labs help identify potential drug interactions and guide deprescribing strategies.
Nutritional Status
While not a standard lab, consider albumin and prealbumin if available, as weight loss is preserved across age groups but effects on muscle mass and sarcopenia remain unexplored 4. Clinical phenotype-driven selection is essential to balance benefits and risks regarding nutritional status and frailty 4.
Gastrointestinal Risk
Document baseline gastrointestinal symptoms, as 10-30% of older users experience predominantly gastrointestinal adverse events, and discontinuation due to intolerance appears more frequent in older adults 4. The slowing of gastric emptying increases aspiration risk during procedures 2.
Risk Stratification Context
For this 75-year-old woman, classify her cardiovascular risk using the ESC framework 1:
- Very high risk if she has established CVD, target organ damage (proteinuria, eGFR <30, LVH, retinopathy), or ≥3 major risk factors
- High risk if diabetes duration ≥10 years without target organ damage plus any additional risk factor
This classification, combined with lab results, determines the strength of indication for GLP-1 RA therapy, as these agents show 9% reduction in cardiovascular mortality, 9% reduction in MI, 16% reduction in stroke, and 82% reduction in all-cause mortality in patients ≥80 years compared to DPP4 inhibitors 5.